Carregant...
Systemic treatment for metastatic prostate cancer
The management of metastatic prostate cancer (mPCa) has changed over the past ten years. Several new drugs have been approved with significant overall survival benefits in metastatic castration resistant prostate cancer (PCa) including chemotherapy (docetaxel, cabazitaxel), new hormonal therapies (a...
Guardat en:
| Publicat a: | Asian J Urol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Second Military Medical University
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6488732/ https://ncbi.nlm.nih.gov/pubmed/31061802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajur.2019.02.002 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|